Stage III NSCLC

After chemoradiation, 57% of stage III lung cancer patients are dead within five years1.

Two thirds have progressed.2 Stage III accounts for roughly a quarter of all non-small cell diagnoses.3

57%1
of stage III patients are dead within five years on the current standard of care
Two thirds2
have progressed
A quarter3
of non-small cell diagnoses are stage III

More than half of stage III lung cancer patients die within five years of treatment given with the intent to cure. That fraction is what we are here to change.

Please note: Nyxeris Bio operates in a stealth capacity.

Someone on the team reads every message. Details are held only so that we can answer. Privacy policy.